. Author manuscript; available in PMC: 2023 Jul 1.

Published in final edited form as: Pediatr Infect Dis J. 2022 Jun 7;41(7):556–562. doi: 10.1097/INF.0000000000003559

Table 4:

Clinical Effectiveness

Outcomes	Solithromycin		Comparator
All ages	n/N (%)	95% CI	n/N (%)	95% CI
Clinical improvement¹	40/62 (64.5)	51%, 76%	17/21 (81.0)	58%, 95%
Early clinical response²	34/51 (66.7)	52%, 79%	7/15 (46.7)	21%, 73%
Clinical cure³	36/60 (60.0)	47%, 72%	13/19 (68.4)	43%, 87%

2 months – 5 years
Clinical improvement¹	5/10 (50.0)	19%, 81%	2/3 (66.7)	9%, 99%
Early clinical response²	4/9 (44.4)	14%, 79%	1/5 (20.0)	1%, 72%
Clinical cure³	4/9 (44.4)	14%, 79%	3/4 (75.0)	19%, 99%

6-17 years
Clinical improvement¹	35/52 (67.3)	53%, 80%	15/18 (83.3)	59%, 96%
Early clinical response²	30/42 (71.4)	55%, 84%	6/10 (60.0)	26%, 88%
Clinical cure³	32/51 (62.7)	48%, 76%	10/15 (66.7)	38%, 88%

^{1 –}

assessed on last day of treatment (+48 hours) and defined as an improvement in at least one CABP presenting sign or symptom with no deterioration in any sign or symptom of CABP, no development of new sign or symptom of CABP, and no requirement for additional or alternative antimicrobial therapy

^{2 –}

assessed on days 2-4 and defined similarly to clinical improvement

^{3 –}

assessed on day 16 post-randomization (± 4 days) and defined resolution of all presenting CABP signs and symptoms and no requirement for an additional antibiotic, CI – confidence intervals